Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ZGNX Stock Summary
In the News

Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
EMERYVILLE, Calif., March 04, 2022 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, announced that new data from the company's research and development program for FINTEPLA® (fenfluramine) in Lennox Gastaut syndrome (LGS) will be presented at the hybrid American Academy of Neurology (AAN) Annual Meeting 2022, in-person in Seattle (April 2-7) and held virtually (April 24-26).

Zogenix (ZGNX) Reports Q4 Loss, Tops Revenue Estimates
Zogenix (ZGNX) delivered earnings and revenue surprises of -8.89% and 1.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Zogenix Flew Higher Before Leveling Off This Week
The company attracts a determined suitor from abroad.

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist
Which biotech stocks are you watching today?

Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.

Zogenix (ZGNX) Stock Jumps 65.7%: Will It Continue to Soar?
Zogenix (ZGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today
Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal. The post ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today appeared first on InvestorPlace.

Why Zogenix Stock Is on Fire Today
A buyout deal is lighting a fire underneath the biotech's shares today.

Why Zogenix Shares Are Soaring Today
Zogenix Inc (NASDAQ: ZGNX) is trading significantly higher Wednesday morning after the company announced it received a proposal to be acquired by UCB for approximately $1.9 billion. Under terms of the agreement, UCB will offer to purchase all outstanding shares of Zogenix for $26 per share in cash at closing.

Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today
The stock price of Zogenix, Inc. (NASDAQ: ZGNX) increased by over 60% pre-market today. This is why it happened.
ZGNX Financial details
ZGNX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
Metric | History | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.36 | 0 | 0.08 | 0.25 | 1.52 | |
Net income per share | -4.65 | -3.27 | -9.74 | -3.9 | -4.24 | |
Operating cash flow per share | -2.78 | -2.95 | -2.59 | -3.12 | -3.45 | |
Free cash flow per share | -2.78 | -2.97 | -2.81 | -3.33 | -3.45 | |
Cash per share | 10.75 | 13.57 | 5.83 | 9.41 | 5.62 | |
Book value per share | 11.04 | 13.8 | 5.69 | 6.89 | 3.33 | |
Tangible book value per share | 7.06 | 10.93 | 3.17 | 4.93 | 1.53 | |
Share holders equity per share | 11.04 | 13.8 | 5.69 | 6.89 | 3.33 | |
Interest debt per share | 0.1 | 0 | 0.03 | 2.88 | 3.42 | |
Market cap | 1.09B | 1.38B | 2.25B | 1.07B | 872.43M | |
Enterprise value | 799.9M | 1.31B | 2.2B | 1.06B | 939.73M | |
P/E ratio | -8.62 | -11.15 | -5.35 | -5.13 | -3.84 | |
Price to sales ratio | 111.33 | 0 | 615.47 | 78.66 | 10.68 | |
POCF ratio | -14.41 | -12.37 | -20.13 | -6.41 | -4.71 | |
PFCF ratio | -14.4 | -12.26 | -18.55 | -6 | -4.71 | |
P/B Ratio | 3.63 | 2.64 | 9.16 | 2.9 | 4.87 | |
PTB ratio | 3.63 | 2.64 | 9.16 | 2.9 | 4.87 | |
EV to sales | 81.45 | 0 | 601.77 | 77.5 | 11.5 | |
Enterprise value over EBITDA | -6.46 | -10.61 | -5.25 | -4.86 | -4.64 | |
EV to operating cash flow | -10.54 | -11.76 | -19.68 | -6.31 | -5.07 | |
EV to free cash flow | -10.53 | -11.65 | -18.14 | -5.91 | -5.07 | |
Earnings yield | -0.12 | -0.09 | -0.19 | -0.2 | -0.26 | |
Free cash flow yield | -0.07 | -0.08 | -0.05 | -0.17 | -0.21 | |
Debt to equity | 0.39 | 0.24 | 0.69 | 0.76 | 1.62 | |
Debt to assets | 0.28 | 0.19 | 0.41 | 0.43 | 0.62 | |
Net debt to EBITDA | 2.37 | 0.55 | 0.12 | 0.07 | -0.33 | |
Current ratio | 14.52 | 9.13 | 3.01 | 6.31 | 3.63 | |
Interest coverage | -45.36 | -23.53K | -214.91K | -65.9 | -14.67 | |
Income quality | 0.6 | 0.9 | 0.27 | 0.8 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 2.15 | 0 | 9.22 | 7.3 | 0 | |
Research and developement to revenue | 6.87 | 0 | 31.7 | 10.12 | 1.75 | |
Intangibles to total assets | 0.26 | 0.17 | 0.26 | 0.16 | 0.21 | |
Capex to operating cash flow | 0 | 0.01 | 0.09 | 0.07 | 0 | |
Capex to revenue | -0.01 | 0 | -2.6 | -0.83 | 0 | |
Capex to depreciation | -0.18 | -6.57 | -7.49 | -2.08 | -0.01 | |
Stock based compensation to revenue | 0.63 | 0 | 5.82 | 2.14 | 0.43 | |
Graham number | 33.98 | 31.86 | 35.31 | 24.58 | 17.82 | |
ROIC | 0.69 | -0.28 | -1.52 | -0.75 | -0.92 | |
Return on tangible assets | -0.41 | -0.23 | -1.37 | -0.38 | -0.61 | |
Graham Net | 6.5 | 10.26 | 1.9 | 4.23 | 0.42 | |
Working capital | 283.72M | 474.36M | 191.85M | 439.46M | 256.87M | |
Tangible asset value | 192.79M | 414.07M | 136.33M | 264.88M | 82.06M | |
Net current asset value | 188.61M | 407.2M | 118.05M | 240.71M | 65.05M | |
Invested capital | 0 | 0 | 0.01 | 0.41 | 0.94 | |
Average receivables | 6.29M | 0 | 0 | 1.91M | 6.98M | |
Average payables | 3.95M | 5.67M | 7.98M | 9.96M | 16.97M | |
Average inventory | 3.52M | 0 | 0 | 513K | 3.26M | |
Days sales outstanding | 0 | 0 | 0 | 102.31 | 45.3 | |
Days payables outstanding | 114.17 | 0 | 0 | 8.04K | 1.66K | |
Days of inventory on hand | 0 | 0 | 0 | 690.94 | 414.68 | |
Receivables turnover | 0 | 0 | 0 | 3.57 | 8.06 | |
Payables turnover | 3.2 | 0 | 0 | 0.05 | 0.22 | |
Inventory turnover | 0 | 0 | 0 | 0.53 | 0.88 | |
ROE | -0.42 | -0.24 | -1.71 | -0.57 | -1.27 | |
Capex per share | 0 | -0.03 | -0.22 | -0.21 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-12-31 for Q4
Metric | History | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.15 | 0.25 | 0.34 | 0.4 | 0.48 | |
Net income per share | -1.26 | -1 | -1.05 | -1.04 | -0.98 | |
Operating cash flow per share | -0.69 | -0.97 | -0.77 | -0.85 | -0.73 | |
Free cash flow per share | -0.8 | -0.97 | -0.77 | -0.85 | -0.73 | |
Cash per share | 9.07 | 7.81 | 7.04 | 6.14 | 5.39 | |
Book value per share | 6.64 | 5.76 | 4.89 | 4.01 | 3.2 | |
Tangible book value per share | 4.76 | 3.92 | 3.08 | 2.24 | 1.47 | |
Share holders equity per share | 6.64 | 5.76 | 4.89 | 4.01 | 3.2 | |
Interest debt per share | 2.78 | 2.99 | 3.02 | 3.05 | 3.08 | |
Market cap | 1.11B | 1.09B | 964.85M | 849.2M | 910.05M | |
Enterprise value | 1.1B | 1.16B | 990.68M | 909.64M | 977.35M | |
P/E ratio | -3.97 | -4.89 | -4.1 | -3.66 | -4.15 | |
Price to sales ratio | 130.94 | 79.53 | 51.35 | 37.56 | 34.2 | |
POCF ratio | -29.18 | -20.21 | -22.47 | -17.92 | -22.13 | |
PFCF ratio | -25.09 | -20.17 | -22.47 | -17.92 | -22.13 | |
P/B Ratio | 3.01 | 3.39 | 3.54 | 3.79 | 5.08 | |
PTB ratio | 3.01 | 3.39 | 3.54 | 3.79 | 5.08 | |
EV to sales | 129.07 | 85.13 | 52.73 | 40.23 | 36.73 | |
Enterprise value over EBITDA | -17.14 | -23.52 | -18.78 | -17.56 | -20.15 | |
EV to operating cash flow | -28.76 | -21.63 | -23.08 | -19.2 | -23.76 | |
EV to free cash flow | -24.73 | -21.59 | -23.08 | -19.2 | -23.76 | |
Earnings yield | -0.06 | -0.05 | -0.06 | -0.07 | -0.06 | |
Free cash flow yield | -0.04 | -0.05 | -0.04 | -0.06 | -0.05 | |
Debt to equity | 0.76 | 0.81 | 0.98 | 1.22 | 1.62 | |
Debt to assets | 0.43 | 0.45 | 0.49 | 0.55 | 0.62 | |
Net debt to EBITDA | 0.25 | -1.55 | -0.49 | -1.17 | -1.39 | |
Current ratio | 6.31 | 7.77 | 6.01 | 4.79 | 3.63 | |
Interest coverage | -18.03 | -13.86 | -14.63 | -14 | -16.14 | |
Income quality | 0.54 | 0.97 | 0.73 | 0.82 | 0.75 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 3.44 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 4.23 | 2.26 | 1.95 | 1.47 | 1.57 | |
Intangibles to total assets | 0.16 | 0.18 | 0.19 | 0.2 | 0.21 | |
Capex to operating cash flow | 0.16 | 0 | 0 | 0 | 0 | |
Capex to revenue | -0.73 | -0.01 | 0 | 0 | 0 | |
Capex to depreciation | -2.64 | -0.04 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0.86 | 0.59 | 0.51 | 0.36 | 0.36 | |
Graham number | 13.72 | 11.37 | 10.77 | 9.68 | 8.39 | |
ROIC | -0.22 | -0.13 | -0.22 | -0.2 | -0.26 | |
Return on tangible assets | -0.13 | -0.12 | -0.13 | -0.15 | -0.15 | |
Graham Net | 4.08 | 3.25 | 2.39 | 1.42 | 0.4 | |
Working capital | 439.46M | 396.2M | 347.05M | 297.04M | 256.87M | |
Tangible asset value | 264.88M | 218.46M | 172.01M | 125.42M | 82.06M | |
Net current asset value | 240.71M | 195.05M | 149.18M | 102.77M | 65.05M | |
Invested capital | 0.41 | 0.51 | 0.6 | 0.74 | 0.94 | |
Average receivables | 2.57M | 4.97M | 6.91M | 8.59M | 9.81M | |
Average payables | 9.58M | 11.95M | 11.4M | 11.47M | 17.06M | |
Average inventory | 1.02M | 1.68M | 2.62M | 3.21M | 4.5M | |
Days sales outstanding | 40.48 | 40.24 | 36.89 | 37.76 | 34.29 | |
Days payables outstanding | 2.67K | 1.59K | 797.7 | 842.48 | 1.21K | |
Days of inventory on hand | 229.7 | 309.41 | 215.28 | 243.57 | 301.02 | |
Receivables turnover | 2.22 | 2.24 | 2.44 | 2.38 | 2.62 | |
Payables turnover | 0.03 | 0.06 | 0.11 | 0.11 | 0.07 | |
Inventory turnover | 0.39 | 0.29 | 0.42 | 0.37 | 0.3 | |
ROE | -0.19 | -0.17 | -0.22 | -0.26 | -0.31 | |
Capex per share | -0.11 | 0 | 0 | 0 | 0 |
ZGNX Frequently Asked Questions
What is Zogenix, Inc. stock symbol ?
Zogenix, Inc. is a US stock , located in Emeryville of California and trading under the symbol ZGNX
Is Zogenix, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $26. The lowest prediction is $26 and the highest is $26
What is ZGNX stock prediction ?
What is Zogenix, Inc. stock quote today ?
Zogenix, Inc. stock price is $26.68 today.
Is Zogenix, Inc. stock public?
Yes, Zogenix, Inc. is a publicly traded company.